<h4>Background</h4>Neoadjuvant chemotherapy (NAC) in up to 40%-60% of node-positive (cN+) breast cancer patients allows nodal pathological complete response, particularly in Her2+ and triple-negative subtypes. The gene discussed is ERBB2; the disease is breast carcinoma.